NCT06483334
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06483334
Title A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)
Acronym MK-3475-04C/​KEYMAKER-U04
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Merck Sharp & Dohme LLC
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | NLD | ITA | ISR | GBR | FRA | ESP | CAN

Facility Status City State Zip Country Details
University of California San Francisco HDFCCC ( Site 4044) San Francisco California 94158 United States Details
University of Chicago Medical Center ( Site 4037) Chicago Illinois 60637 United States Details
Indiana University Melvin and Bren Simon Cancer Center ( Site 4011) Indianapolis Indiana 46202 United States Details
Dana-Farber Cancer Institute ( Site 4047) Boston Massachusetts 02115 United States Details
Siteman Cancer Center ( Site 4038) St Louis Missouri 63108 United States Details
Icahn School of Medicine at Mount Sinai ( Site 4018) New York New York 10029 United States Details
Cleveland Clinic-Taussig Cancer Center ( Site 4036) Cleveland Ohio 44195 United States Details
Huntsman Cancer Institute-HCI Clinical Trials Office ( Site 4041) Salt Lake City Utah 84112 United States Details
The Ottawa Hospital - General Campus ( Site 4105) Ottawa Ontario K1H 8L6 Canada Details
Princess Margaret Cancer Centre ( Site 4106) Toronto Ontario M5G 2M9 Canada Details
Centre Hospitalier Lyon Sud ( Site 4606) Pierre-Bénite Auvergne-Rhône-Alpes 69310 France Details
Rambam Health Care Campus ( Site 4501) Haifa 3109601 Israel Details
Rabin Medical Center-Oncology ( Site 4504) Petah Tikva 4941492 Israel Details
Sheba Medical Center-ONCOLOGY ( Site 4503) Ramat Gan 5265601 Israel Details
Ospedale San Raffaele-Oncologia Medica ( Site 4403) Milan Lombardy 20132 Italy Details
Fondazione IRCCS Istituto Nazionale dei Tumori ( Site 4405) Milan 20133 Italy Details
Istituto Nazionale Tumori IRCCS Fondazione Pascale ( Site 4406) Napoli 80131 Italy Details
Nederlands Kanker Instituut - Antoni van Leeuwenhoek - NKI-AVL ( Site 4302) Amsterdam North Holland 1066 CX Netherlands Details
Severance Hospital, Yonsei University Health System-Medical oncology ( Site 4903) Seoul 03722 South Korea Details
Asan Medical Center-Department of Oncology ( Site 4901) Seoul 05505 South Korea Details
Samsung Medical Center ( Site 4902) Seoul 06351 South Korea Details
Hospital Universitari Vall d'Hebron-Oncology ( Site 4767) Barcelona 08035 Spain Details
Hospital Clinico San Carlos ( Site 4765) Madrid 28040 Spain Details
National Cheng Kung University Hospital-Clinical Trial Center ( Site 4803) Tainan 704 Taiwan Details
St Bartholomew s Hospital ( Site 4206) London London, City of EC1A 7BE United Kingdom Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field